7. Therapy
AE therapy has undergone a true revolution in recent years. We are on the way to being spoilt for choice in deciding which systemic therapy to use. What remains to be seen, however, is which subtype of AE will respond to which new targeted drug. Tailored treatment strategy in AE depends on the individual patients’ age, history and disease severity, evaluated by assessing both objective and subjective [108, 109]. Interestingly, unique T-cell subsets and cytokine patterns in pediatric compared to adult AE patients urge for age-specific therapies [110] [108]. Considering the multidimensional nature of AE, effective disease management incorporates different pillars of treatment. Besides basic skin care and individual pharmacological approaches, patient education and self-management strategies that address social and environmental factors have to be included – not only to optimize individual outcomes, but also to reduce unnecessary costs associated with the management of AE [111]. The knowledge and therapy options expand rapidly in AE and the current standards for diagnosis and therapy are nicely summarized by Wollenberg et al [112, 113]. Interestingly, a recent study has shown that patients self-reported disease severity seems to be correlated with treatment satisfaction of AE patients [114].